• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, June 27, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

MU researchers describe catatonia in Down syndrome

Bioengineer by Bioengineer
November 19, 2019
in Health
Reading Time: 2 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

First longitudinal study highlights positive responses to established catatonia therapies

IMAGE

Credit: MU News Bureau


COLUMBIA, Mo. – Down syndrome, due to an extra chromosome 21, occurs in 250,000 children and adults in the United States, making it the country’s most common chromosomal disorder. Inherited heart defects, thyroid cancer, celiac disease and developmental disabilities are common Down syndrome complications. Only recently has catatonia, a behavioral condition marked by new onset immobility, mutism, withdrawal and other behavioral abnormalities, been recognized in Down syndrome.

While considerable research has been done on Down syndrome, little is known about associated catatonia. Now, researchers at the University of Missouri have conducted the first longitudinal study of consecutively diagnosed individuals with catatonia in order to identify the most effective treatments and outcomes.

Judith Miles, professor emerita of child health-genetics in the MU Thompson Center for Autism and Neurodevelopmental Disorders, thoroughly assessed seven adolescents with Down syndrome and diagnosed with catatonia between 2013 and 2018.

“As this was the first well-studied group of patients with Down syndrome who developed catatonia, we collected a comprehensive data set of medical, developmental, demographic, family, social and genetic information,” Miles said. “By involving the patients’ families throughout the process, we were able to monitor progress over time in a patient-centered way.”

Miles found catatonia in young people with Down syndrome, for the most part, resembles catatonia complicating other psychiatric and medical disorders. Lorazepam, a sedative drug that helps restore the balance of neurotransmitters in the brain, and electroconvulsive therapy, which involves a brief electrical stimulation of the brain while the patient is under anesthesia, both resulted in reduced behavioral symptoms over time. The research highlights the importance of sustained treatment to help patients with Down syndrome and catatonia maintain recovery long-term.

“This research can help families, physicians and psychiatrists who take care of kids with catatonia,” Miles said. “Our main goal is to enhance medical services and treatment options in order to ultimately improve health outcomes.”

###

The study “Catatonia in Down syndrome: systematic approach to diagnosis, treatment and outcome assessment based on a case series of seven patients” was recently published in Neuropsychiatric Disease and Treatment.

Media Contact
Brian Consiglio
[email protected]
573-882-9144

Original Source

https://news.missouri.edu/2019/mu-researchers-describe-catatonia-in-down-syndrome-and-highlight-positive-responses-to-established-catatonia-therapies/

Related Journal Article

http://dx.doi.org/10.2147/NDT.S210613

Tags: AlzheimerGeneticsHealth CareMedicine/Healthneurobiology
Share12Tweet8Share2ShareShareShare2

Related Posts

Tracking Lanthanide-Labeled Microplastics in Plants

June 25, 2026

Neural Design Enables Zero-Shot Drug-Binding Proteins

June 25, 2026

Genomic Insights into Human Skin Fungi Diversity

June 25, 2026

Chiral Laser Gyroscopes Surpass Lock-In Limit

June 25, 2026
Please login to join discussion

POPULAR NEWS

  • Saying Goodbye to PGY-6: Pediatric Fellowship Realities

    103 shares
    Share 41 Tweet 26
  • Multi-Hospital Study Reveals Long Covid Burden Is Twice as High as Current Estimates

    92 shares
    Share 36 Tweet 23
  • Detection of EDCs in Breast Milk and Infant Urine Up to Six Months Highlights Early Exposure Risks

    77 shares
    Share 31 Tweet 19
  • New Drug Candidate Developed at McMaster Shows Potential for Treating Brain Cancer

    58 shares
    Share 23 Tweet 15

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Tracking Lanthanide-Labeled Microplastics in Plants

POSTECH Researchers Slash Cost of Reconstituted Cell-Free Systems by 95%

AI and Physics Collaborate to Design Advanced Hydrogen Storage Materials

Subscribe to Blog via Email

Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm' to start subscribing.

Join 82 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.